mesna 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
	1711	3375-50-6

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: mesna mercaptoethanesulfonic acid reduced coenzyme M	A sulfhydryl compound used to prevent urothelial toxicity by inactivating metabolites from ANTINEOPLASTIC AGENTS, such as IFOSFAMIDE or CYCLOPHOSPHAMIDE. Molecular weight: 142.19 Formula: C2H6O3S2 CLOGP: -1.55 LIPINSKI: 0 HAC: 3 HDO: 1 TPSA: 54.37 ALOGS: -1.05 ROTB: 2 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

mesna
mercaptoethanesulfonic acid
reduced coenzyme M

A sulfhydryl compound used to prevent urothelial toxicity by inactivating metabolites from ANTINEOPLASTIC AGENTS, such as IFOSFAMIDE or CYCLOPHOSPHAMIDE.

Molecular weight: 142.19
Formula: C2H6O3S2
CLOGP: -1.55
LIPINSKI: 0
HAC: 3
HDO: 1
TPSA: 54.37
ALOGS: -1.05
ROTB: 2

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
1.20	g	Inhal.solution

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	1	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	28.13 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability)	62 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution)	0.65 L/kg	Lombardo F, Berellini G, Obach RS
CL (Clearance)	20.50 mL/min/kg	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	0.36 hours	Lombardo F, Berellini G, Obach RS

Approvals:

Date	Agency	Company	Orphan
Dec. 30, 1988	FDA	BAXTER HLTHCARE

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Febrile neutropenia	685.65	24.11	331	8461	118118	63362112
Encephalopathy	407.63	24.11	165	8627	38455	63441775
Mucosal inflammation	254.87	24.11	126	8666	46802	63433428
Pancytopenia	209.70	24.11	143	8649	96790	63383440
Neutropenia	204.54	24.11	179	8613	174826	63305404
Pyrexia	145.19	24.11	244	8548	470234	63009996
Cystitis haemorrhagic	109.69	24.11	35	8757	4088	63476142
Thrombocytopenia	105.80	24.11	117	8675	151040	63329190
Neurotoxicity	102.25	24.11	49	8743	16941	63463289
Leukopenia	93.92	24.11	81	8711	77209	63403021
Febrile bone marrow aplasia	86.49	24.11	34	8758	7291	63472939
Haematotoxicity	75.12	24.11	33	8759	9343	63470887
Toxic encephalopathy	72.31	24.11	29	8763	6550	63473680
Product use in unapproved indication	71.70	24.11	105	8687	178975	63301255
Cytomegalovirus infection	70.57	24.11	41	8751	20911	63459319
Aplastic anaemia	64.96	24.11	30	8762	9539	63470691
T-cell lymphoma refractory	53.05	24.11	9	8783	57	63480173
Anaemia	52.04	24.11	121	8671	293309	63186921
Sepsis	51.69	24.11	83	8709	153040	63327190
Venoocclusive liver disease	48.63	24.11	20	8772	4815	63475415
Cytokine release syndrome	48.17	24.11	28	8764	14286	63465944
Arthralgia	46.49	24.11	11	8781	569699	62910531
Hypokalaemia	44.60	24.11	63	8729	103741	63376489
Idiopathic pneumonia syndrome	43.07	24.11	10	8782	350	63479880
Bone marrow failure	42.40	24.11	34	8758	29256	63450974
Drug ineffective	37.93	24.11	54	8738	1044711	62435519
Vena cava thrombosis	36.19	24.11	13	8779	2174	63478056
Pneumothorax	35.07	24.11	24	8768	16237	63463993
Polyneuropathy	34.99	24.11	23	8769	14566	63465664
Platelet count decreased	33.88	24.11	59	8733	116063	63364167
BK polyomavirus test positive	33.31	24.11	6	8786	56	63480174
Myelosuppression	33.21	24.11	27	8765	23676	63456554
Amniotic fluid index decreased	32.75	24.11	5	8787	14	63480216
Chronic hepatitis B	32.75	24.11	8	8784	349	63479881
Pain	32.42	24.11	33	8759	740595	62739635
Mitral valve disease	31.00	24.11	12	8780	2468	63477762
Disease progression	30.28	24.11	58	8734	122700	63357530
Cardiotoxicity	29.70	24.11	17	8775	8421	63471809
Drug intolerance	29.35	24.11	4	8788	308657	63171573
Peripheral sensory neuropathy	28.91	24.11	16	8776	7435	63472795
Multiple organ dysfunction syndrome	28.23	24.11	37	8755	56715	63423515
Off label use	28.03	24.11	174	8618	674288	62805942
Hyperuricaemia	27.85	24.11	14	8778	5356	63474874
Periorbital cellulitis	27.26	24.11	8	8784	705	63479525
Blood phosphorus decreased	27.26	24.11	13	8779	4440	63475790
Posterior reversible encephalopathy syndrome	26.96	24.11	21	8771	17324	63462906
Peripheral swelling	26.37	24.11	3	8789	265939	63214291
Ejection fraction decreased	26.27	24.11	23	8769	22309	63457921
Hepatocellular injury	25.97	24.11	25	8767	27356	63452874
Depersonalisation/derealisation disorder	25.92	24.11	9	8783	1363	63478867
Candida sepsis	25.87	24.11	9	8783	1371	63478859
Hepatitis E	25.47	24.11	9	8783	1435	63478795
Candida test positive	25.46	24.11	8	8784	888	63479342
Mental status changes	24.82	24.11	29	8763	39570	63440660
Aplasia	24.75	24.11	12	8780	4247	63475983

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Febrile neutropenia	682.42	21.70	452	10012	136397	34810070
Encephalopathy	286.35	21.70	160	10304	35159	34911308
Cystitis haemorrhagic	152.13	21.70	59	10405	5620	34940847
Pyrexia	142.40	21.70	309	10155	332704	34613763
Neutropenia	129.30	21.70	194	10270	156584	34789883
Mucosal inflammation	123.38	21.70	98	10366	38524	34907943
Venoocclusive liver disease	107.70	21.70	51	10413	7915	34938552
Cytokine release syndrome	90.55	21.70	66	10398	22811	34923656
Aplastic anaemia	89.58	21.70	48	10416	9668	34936799
Pancytopenia	80.02	21.70	119	10345	95038	34851429
Febrile bone marrow aplasia	74.12	21.70	40	10424	8169	34938298
Aplasia	70.17	21.70	32	10432	4556	34941911
SARS-CoV-2 test negative	63.97	21.70	20	10444	1000	34945467
Anal inflammation	63.16	21.70	21	10443	1279	34945188
Thrombocytopenia	62.91	21.70	142	10322	156105	34790362
Venoocclusive disease	60.18	21.70	25	10439	2842	34943625
Myelosuppression	59.57	21.70	48	10416	19217	34927250
Leukopenia	59.20	21.70	83	10381	62773	34883694
Proctalgia	57.64	21.70	30	10434	5693	34940774
Fanconi syndrome	57.41	21.70	21	10443	1699	34944768
Haematotoxicity	55.27	21.70	33	10431	8161	34938306
Neutrophil count decreased	53.43	21.70	71	10393	51033	34895434
Stomatitis	47.44	21.70	61	10403	42453	34904014
Accident	46.69	21.70	25	10439	5022	34941445
Acute graft versus host disease	45.98	21.70	27	10437	6476	34939991
Neurotoxicity	45.61	21.70	40	10424	17970	34928497
Foetal growth restriction	45.57	21.70	23	10441	4094	34942373
Platelet transfusion	44.95	21.70	17	10447	1509	34944958
Oesophagitis	36.72	21.70	31	10433	13230	34933237
Fall	36.65	21.70	8	10456	202877	34743590
Haemorrhoids	34.18	21.70	31	10433	14544	34931923
Death	33.64	21.70	42	10422	398007	34548460
Angiodysplasia	32.72	21.70	11	10453	693	34945774
Bone marrow failure	32.66	21.70	42	10422	29211	34917256
Fusarium infection	30.87	21.70	12	10452	1148	34945319
Chronic graft versus host disease	30.50	21.70	18	10446	4355	34942112
Septic shock	28.50	21.70	65	10399	71769	34874698
Polyneuropathy	26.11	21.70	27	10437	14869	34931598
Vomiting	25.99	21.70	144	10320	247477	34698990
Myocardial infarction	25.82	21.70	3	10461	121082	34825385
Engraftment syndrome	25.42	21.70	10	10454	987	34945480
Malassezia infection	25.19	21.70	5	10459	35	34946432
Drug therapeutic incompatibility	24.65	21.70	6	10458	116	34946351
Body temperature increased	24.37	21.70	28	10436	17340	34929127
Herpes zoster reactivation	23.52	21.70	7	10457	296	34946171
Agranulocytosis	23.20	21.70	32	10432	23789	34922678
Acute graft versus host disease in skin	22.85	21.70	16	10448	5185	34941282
Toxic encephalopathy	22.71	21.70	16	10448	5233	34941234
Anaemia	22.70	21.70	133	10331	233202	34713265
Neutropenic sepsis	22.43	21.70	24	10440	13743	34932724
Combined immunodeficiency	22.19	21.70	5	10459	68	34946399
Cytopenia	22.19	21.70	23	10441	12700	34933767

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Febrile neutropenia	1242.72	19.95	720	17076	230279	79496313
Encephalopathy	639.43	19.95	308	17488	67089	79659503
Mucosal inflammation	312.41	19.95	200	17596	75380	79651212
Pancytopenia	307.24	19.95	271	17525	165474	79561118
Neutropenia	294.77	19.95	341	17455	287369	79439223
Pyrexia	260.61	19.95	507	17289	678202	79048390
Cystitis haemorrhagic	252.78	19.95	90	17706	9082	79717510
Febrile bone marrow aplasia	165.38	19.95	73	17723	12947	79713645
Aplastic anaemia	157.93	19.95	78	17718	17827	79708765
Thrombocytopenia	143.55	19.95	231	17565	265028	79461564
Venoocclusive liver disease	143.09	19.95	64	17732	11707	79714885
Pseudomonal sepsis	134.63	19.95	51	17745	6123	79720469
Leukopenia	132.32	19.95	146	17650	116367	79610225
Neurotoxicity	126.68	19.95	83	17713	32435	79694157
Haematotoxicity	126.23	19.95	64	17732	15455	79711137
Secondary immunodeficiency	113.38	19.95	38	17758	3196	79723396
Cytokine release syndrome	112.05	19.95	80	17716	35918	79690674
Myelosuppression	88.97	19.95	73	17723	40223	79686369
Toxic encephalopathy	86.73	19.95	45	17751	11395	79715197
Aplasia	83.95	19.95	39	17757	7781	79718811
Arthralgia	83.03	19.95	14	17782	571789	79154803
SARS-CoV-2 test negative	81.02	19.95	24	17772	1347	79725245
Fanconi syndrome	78.57	19.95	28	17768	2828	79723764
Product use in unapproved indication	77.66	19.95	172	17624	250187	79476405
Anal inflammation	75.72	19.95	23	17773	1407	79725185
Bacterial infection	73.99	19.95	59	17737	31221	79695371
Venoocclusive disease	72.47	19.95	30	17766	4543	79722049
Anaemia	68.99	19.95	237	17559	444778	79281814
Bone marrow failure	66.70	19.95	69	17727	51038	79675554
Polyneuropathy	62.40	19.95	48	17748	24103	79702489
Bronchopulmonary aspergillosis	59.12	19.95	45	17751	22249	79704343
Cytomegalovirus viraemia	58.05	19.95	36	17760	12785	79713807
Platelet transfusion	57.10	19.95	21	17775	2321	79724271
Neutrophil count decreased	55.05	19.95	85	17711	93874	79632718
Lymphoid tissue hypoplasia	53.74	19.95	16	17780	914	79725678
Thymus hypoplasia	53.02	19.95	16	17780	957	79725635
Drug ineffective	52.85	19.95	101	17695	1080812	78645780
Acute graft versus host disease	52.35	19.95	31	17765	10136	79716456
Sepsis	49.33	19.95	152	17644	269276	79457316
Mycobacterium chelonae infection	48.93	19.95	19	17777	2437	79724155
T-cell lymphoma refractory	48.75	19.95	9	17787	57	79726535
Off label use	48.63	19.95	357	17439	906858	78819734
Septic shock	48.16	19.95	93	17703	122708	79603884
Cytomegalovirus infection	47.58	19.95	53	17743	42591	79684001
Proctalgia	45.07	19.95	28	17768	9973	79716619
Stomatitis	42.28	19.95	98	17698	146659	79579933
Idiopathic pneumonia syndrome	42.16	19.95	12	17784	584	79726008
Neutropenic sepsis	41.69	19.95	40	17756	27024	79699568
Viral infection	40.52	19.95	49	17747	42967	79683625
Peripheral swelling	40.42	19.95	6	17790	269611	79456981
White blood cell count decreased	38.98	19.95	111	17685	188177	79538415
Agranulocytosis	38.73	19.95	49	17747	44981	79681611
Disseminated aspergillosis	38.65	19.95	13	17783	1105	79725487
Accident	37.98	19.95	24	17772	8807	79717785
Drug hypersensitivity	37.82	19.95	10	17786	298906	79427686
Clostridium difficile colitis	35.80	19.95	40	17756	32243	79694349
Chronic graft versus host disease	35.76	19.95	21	17775	6760	79719832
Fatigue	34.82	19.95	100	17696	929627	78796965
Oesophagitis	33.87	19.95	34	17762	24255	79702337
Fungal infection	33.66	19.95	44	17752	41704	79684888
Dizziness	32.44	19.95	42	17754	526399	79200193
Fall	32.05	19.95	37	17759	487592	79239000
Renal tubular disorder	31.37	19.95	19	17777	6467	79720125
Angiodysplasia	31.06	19.95	11	17785	1091	79725501
Acute graft versus host disease in skin	30.92	19.95	20	17776	7638	79718954
Immune effector cell-associated neurotoxicity syndrome	30.55	19.95	18	17778	5830	79720762
Amniotic fluid index decreased	30.37	19.95	5	17791	14	79726578
Hypokalaemia	29.88	19.95	85	17711	143955	79582637
Peripheral sensory neuropathy	29.57	19.95	24	17772	13009	79713583
Nasopharyngitis	29.37	19.95	10	17786	253871	79472721
Fusarium infection	28.97	19.95	12	17784	1820	79724772
Abdominal discomfort	28.79	19.95	10	17786	250717	79475875
Depersonalisation/derealisation disorder	28.78	19.95	12	17784	1850	79724742
Weight increased	28.68	19.95	13	17783	277373	79449219
Platelet count decreased	28.60	19.95	102	17694	194562	79532030
Cystitis viral	27.30	19.95	9	17787	719	79725873
Haemorrhoids	27.13	19.95	33	17763	29095	79697497
Chronic hepatitis B	27.11	19.95	8	17788	443	79726149
Malassezia infection	26.53	19.95	5	17791	36	79726556
Drug intolerance	26.35	19.95	13	17783	264106	79462486
Hepatitis E	26.29	19.95	13	17783	2973	79723619
Swelling	26.01	19.95	8	17788	216703	79509889
Cytopenia	25.65	19.95	27	17769	20356	79706236
Bacteraemia	25.54	19.95	34	17762	32790	79693802
Leukoencephalopathy	25.53	19.95	18	17778	7911	79718681
Aspergillus infection	25.22	19.95	26	17770	19135	79707457
BK polyomavirus test positive	25.01	19.95	6	17790	148	79726444
Bacterial sepsis	24.99	19.95	18	17778	8180	79718412
Multiple organ dysfunction syndrome	24.97	19.95	71	17725	120175	79606417
Hyperbilirubinaemia	24.85	19.95	29	17767	24489	79702103
Contraindicated product administered	24.80	19.95	3	17793	157535	79569057
Pain in extremity	24.66	19.95	27	17769	364511	79362081
Drug therapeutic incompatibility	24.42	19.95	6	17790	164	79726428
Candida test positive	23.62	19.95	9	17787	1097	79725495
Myocardial infarction	23.58	19.95	6	17790	184123	79542469
Pneumothorax	23.06	19.95	30	17766	28293	79698299
Acute kidney injury	23.05	19.95	196	17600	519208	79207384
Hypoalbuminaemia	22.95	19.95	26	17770	21271	79705321
Graft versus host disease	22.75	19.95	22	17774	15004	79711588
Ejection fraction decreased	22.69	19.95	33	17763	34544	79692048
Staphylococcal bacteraemia	22.59	19.95	20	17776	12198	79714394
Cardiotoxicity	22.56	19.95	20	17776	12219	79714373
Candida sepsis	22.30	19.95	11	17785	2502	79724090
Adenovirus infection	22.28	19.95	17	17779	8430	79718162
Confusional state	22.26	19.95	134	17662	317863	79408729
Tumour lysis syndrome	22.10	19.95	27	17769	23912	79702680
Haematuria	22.08	19.95	48	17748	68788	79657804
Mental status changes	21.83	19.95	47	17749	66912	79659680
Fanconi syndrome acquired	21.58	19.95	11	17785	2683	79723909
Engraftment syndrome	21.50	19.95	9	17787	1400	79725192
Periorbital cellulitis	21.38	19.95	8	17788	927	79725665
Blood phosphorus decreased	21.15	19.95	15	17781	6653	79719939
Amniotic fluid volume decreased	21.12	19.95	6	17790	290	79726302
Rhinovirus infection	20.96	19.95	16	17780	7937	79718655
Hypersensitivity	20.56	19.95	17	17779	262222	79464370
Cardiorenal syndrome	20.46	19.95	9	17787	1580	79725012
Aphasia	20.30	19.95	37	17759	46695	79679897
Rash	20.30	19.95	64	17732	578294	79148298
Bladder telangiectasia	20.15	19.95	3	17793	3	79726589
Posterior reversible encephalopathy syndrome	20.10	19.95	27	17769	26254	79700338

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	R05CB05	RESPIRATORY SYSTEM COUGH AND COLD PREPARATIONS EXPECTORANTS, EXCL. COMBINATIONS WITH COUGH SUPPRESSANTS Mucolytics
ATC	V03AF01	VARIOUS ALL OTHER THERAPEUTIC PRODUCTS ALL OTHER THERAPEUTIC PRODUCTS Detoxifying agents for antineoplastic treatment
CHEBI has role	CHEBI:23354	coenzymes
MeSH PA	D020011	Protective Agents

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Testicular Germ Cell Tumor	indication
Prevention of Chemotherapy-Induced Hemorrhagic Cystitis	indication
Ewing's sarcoma	off-label use	76909002	DOID:3369
Burkitt's lymphoma	off-label use	118617000
Non-small cell lung cancer	off-label use	254637007	DOID:3908
Malignant tumor of head and/or neck	off-label use	255056009
Osteosarcoma of bone	off-label use	307576001	DOID:3376
Soft or Connective Tissue Sarcoma	off-label use
Renal tubular acidosis	contraindication	1776003	DOID:14219
Hyperbilirubinemia	contraindication	14783006	DOID:2741
Dehydration	contraindication	34095006
Fanconi syndrome	contraindication	40488004	DOID:1062
Hypokalemia	contraindication	43339004
Leukopenia	contraindication	84828003	DOID:615
Kidney disease	contraindication	90708001	DOID:557
Kidney excision	contraindication	108022006
Liver function tests abnormal	contraindication	166603001
Disease of liver	contraindication	235856003	DOID:409
Impaired wound healing	contraindication	271618001
Anemia	contraindication	271737000	DOID:2355
Pregnancy, function	contraindication	289908002
Thrombocytopenic disorder	contraindication	302215000	DOID:1588
Bone marrow depression	contraindication	307762000
Coma	contraindication	371632003
Impaired cognition	contraindication	386806002
Breastfeeding (mother)	contraindication	413712001
Cancer Chemotherapy Induced Hemorrhagic Cystitis	contraindication
Polyneuropathies	contraindication
Severe Bone Marrow Depression	contraindication
Bone Metastases	contraindication
CNS Toxicity	contraindication

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	0.61	acidic
pKa2	9.77	acidic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

None

External reference:

ID	Source
4019477	VUID
N0000147597	NUI
D01459	KEGG_DRUG
4019477	VANDF
C0000294	UMLSCUI
CHEBI:62955	CHEBI
CHEMBL1098319	ChEMBL_ID
CHEMBL975	ChEMBL_ID
D015080	MESH_DESCRIPTOR_UI
23662354	PUBCHEM_CID
2813	INN_ID
NR7O1405Q9	UNII
DB09110	DRUGBANK_ID
1546354	RXNORM
41498	MMSL
5057	MMSL
d01411	MMSL
002678	NDDF
108821000	SNOMEDCT_US
386922000	SNOMEDCT_US
COM	PDB_CHEM_ID
19767-45-4	SECONDARY_CAS_RN

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
mesna	HUMAN PRESCRIPTION DRUG LABEL	1	0143-9260	INJECTION, SOLUTION	100 mg	INTRAVENOUS	ANDA	25 sections
MESNEX	HUMAN PRESCRIPTION DRUG LABEL	1	0338-1305	INJECTION, SOLUTION	100 mg	INTRAVENOUS	NDA	27 sections
MESNEX	HUMAN PRESCRIPTION DRUG LABEL	1	0338-1305	INJECTION, SOLUTION	100 mg	INTRAVENOUS	NDA	27 sections
MESNEX	HUMAN PRESCRIPTION DRUG LABEL	1	0338-1307	INJECTION, SOLUTION	1 mg	INTRAVENOUS	NDA	24 sections
MESNEX	HUMAN PRESCRIPTION DRUG LABEL	1	0338-1307	INJECTION, SOLUTION	100 mg	INTRAVENOUS	NDA	24 sections
MESNEX	HUMAN PRESCRIPTION DRUG LABEL	1	0338-1307	INJECTION, SOLUTION	100 mg	INTRAVENOUS	NDA	24 sections
MESNA	HUMAN PRESCRIPTION DRUG LABEL	1	10019-951	INJECTION, SOLUTION	100 mg	INTRAVENOUS	NDA	26 sections
MESNA	HUMAN PRESCRIPTION DRUG LABEL	1	10019-951	INJECTION, SOLUTION	100 mg	INTRAVENOUS	NDA	26 sections
MESNA	HUMAN PRESCRIPTION DRUG LABEL	1	10019-953	INJECTION, SOLUTION	100 mg	INTRAVENOUS	NDA	26 sections
MESNA	HUMAN PRESCRIPTION DRUG LABEL	1	10019-953	INJECTION, SOLUTION	100 mg	INTRAVENOUS	NDA	26 sections
Mesna	HUMAN PRESCRIPTION DRUG LABEL	1	25021-201	INJECTION, SOLUTION	100 mg	INTRAVENOUS	ANDA	26 sections
mesna	HUMAN PRESCRIPTION DRUG LABEL	1	62778-304	INJECTION, SOLUTION	100 mg	INTRAVENOUS	ANDA	2 sections
Mesna	Human Prescription Drug Label	1	63323-733	INJECTION, SOLUTION	100 mg	INTRAVENOUS	ANDA	27 sections
MESNEX	HUMAN PRESCRIPTION DRUG LABEL	1	67108-3565	TABLET, FILM COATED	400 mg	ORAL	NDA	26 sections
MESNEX	HUMAN PRESCRIPTION DRUG LABEL	1	67108-3565	TABLET, FILM COATED	400 mg	ORAL	NDA	26 sections
Mesna	Human Prescription Drug Label	1	68083-161	SOLUTION	100 mg	INTRAVENOUS	ANDA	26 sections
Mesna	Human Prescription Drug Label	1	68083-161	SOLUTION	100 mg	INTRAVENOUS	ANDA	26 sections